Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

75 results about "Neisseria sp" patented technology

Neisseria meningitidis serogroup a capsular polysaccharide acetyltransferase, methods and compositions

Provided are recombinant DNA molecules that do not occur in nature encoding an O-acetyltransferase, vectors that direct expression of an O-acetyltransferase, recombinant host cells which express an O-acetyltransferase, methods for recombinant production of an O-acetyltransferase, methods for acetylating capsular polysaccharides, especially those of a Serogroup A Neisseria meningitidis using a recombinant O-acetyltransferase, and immunogenic compositions comprising the acetylated capsular polysaccharide.
Owner:EMORY UNIVERSITY +1

Neisseria genomic sequences and methods of their use

The invention provides methods of obtaining immunogenic proteins from genomic sequences including Neisseria, including the amino acid sequences and the corresponding nucleotide sequences, as well as the genomic sequence of Neisseria meningitidis B. The proteins so obtained are useful antigens for vaccines, immunogenic compositions, and / or diagnostics.
Owner:GLAXOSMITHKLINE BIOLOGICALS SA

85kDa neisserial antigen

An 85 kDa antigen from Neisseria meningitidis and Neisseria gonorrhoeae has been cloned, sequenced and expressed. The antigen is common to diverse strains, serogroups and serotypes of N. meningitidis, and also to N. gonorrhoeae, N. polysaccharia and N. lactamica. The protein sequences of N. meningitidis (serogroups A and B) and N. gonorrhoeae are highly homologous.
Owner:STATENS INST FOR FOLKEHELSE +1

Multi-detection method for drug-resistant sites of neisseria gonorrhoeae

The invention provides a method for detecting mutation of drug-resistant sites of 19 neisseria gonorrhoeae. The method utilizes a multiplex PCR-mass spectrometry method to detect the mutation of the drug-resistant sites of the 19 neisseria gonorrhoeae. The detection method comprises the following steps: 1) designing primers for different drug-resistant sites; 2) carrying out multiplex PCR amplification reaction; 3) treating shrimp alkaline phosphatase; 4) carrying out single base extension reaction; 5) desalting and purifying resin; and 6) carrying out mass spectrometric detection.
Owner:INST OF PATHOGEN BIOLOGY CHINESE ACADEMY OF MEDICAL SCI

Method and kit for multiple detection of drug resistance sites of neisseria gonorrhoeae

The invention belongs to the technical field of molecular biology detection, and relates to a detection method for drug resistance sites, in particular to a method and a kit for multiple detection ofthe drug resistance sites of neisseria gonorrhoeae. A provided specific primer for the multiple detection of the drug resistance sites of the neisseria gonorrhoeae selects drug-resistance-related genes of two drug combinations (ceftriaxone and azithromycin) as target genes for detection, and includes penA, ponA, porB, mtrR, and 23S rRNA. Based on high resolution melting curve analysis technique, the DNA demulsification process is monitored in real time through high resolution melting of PCR products, the mutation condition of the genes is analyzed according to the characteristic change of a melting curve, and thus a basis is provided for determining the drug-resistant condition of the neisseria gonorrhoeae.
Owner:USTAR BIOTECHNOLOGIES (HANGZHOU) CO LTD

Neisserial antigenic peptides

This invention provides, among other things, proteins, polypeptides, and fragments thereof, derived from the bacteria Neisseria meningitidis B. Also provided are nucleic acids encoding for such proteins, polypeptides, and / or fragments, as well as nucleic acids complementary thereto e.g., antisense nucleic acids). Additionally, this invention provides antibodies which bind to the proteins, polypeptides, and / or fragments. This invention further provides expression vectors useful for making the proteins, polypeptides, and / or fragments, as well as host cells transformed with such vectors. This invention also provides compositions of the proteins, polypeptides, fragments, and / or nucleic acids, for use as vaccines, diagnostic reagents, immunogenic compositions, and the like. Methods of making the compositions and methods of treatment with the compositions are also provided. This invention also provides methods of detecting the proteins, polypeptides, fragments, and / or nucleic acids.
Owner:GLAXOSMITHKLINE BIOLOGICALS SA

Antibiotic resistance profile for neisseria gonorrhoeae and use of same in diagnosis and treatment of gonorrhea

The present invention relates to an antibiotic resistance profile for Neisseria gonorrhoeae by assessing the presence of mutations (e.g., SNP) in antibiotic resistant genes that confer bacterial resistance against antibiotics such as penicillin, tetracycline, fluoroquinolones, cephalosporin, macrolides and spectinomycin. There is provided a method and a kit for generating an antibiotic resistance profile for Neisseria gonorrhoeae by utilizing a multiplex PCR to amplify segments of antibiotic-resistant genes, allele-specific primer extension to detect gene mutation, and detection of such gene mutations with gel electrophoresis, capillary electrophoresis, or DNA microarray. The present method provides useful information to physicians relating the antibiotic susceptibility of Neisseria gonorrhoeae against different classes of antibiotics. Relying on this personalized diagnostic tool, physicians can better inform about antibiotic susceptibility and thereby open up medical intervention avenues for treating Neisseria gonorrhoeae with antibiotics. There is provided a therapeutic application of the antibiotic resistance profile that has advantages of: (i) providing a more effective regime for gonorrhea treatment; and (ii) halting the evolutionary pressures towards antibiotic resistance in the Neisseria gonorrhoeae therapy.
Owner:BALASHOV SERGEY +3

Methods for isolating molecular mimetics of unique Neisseria meningitidis serogroup B epitopes

Novel bactericidal antibodies against Neisseria meningitidis serogroup B (“MenB”) are disclosed. The antibodies either do not cross-react or minimally cross-react with host tissue polysialic acid and hence pose minimal risk of autoimmune activity. The antibodies are used to identify molecular mimetics of unique epitopes found on MenB or E. coli K1. Examples of such peptide mimetics are described that elicit serum antibody capable of activating complement-mediated bacteriolysis of MenB. Vaccine compositions containing such mimetics can be used to prevent MenB or E. coli K1 disease without the risk of evoking autoantibody.
Owner:CHILDREN S HOSPITAL &RES CENT AT OAKLAN

Lactoferrin Cleavage of Neisserial Proteins

Meningococcal antigens are cleaved by human lactoferrin. The invention is based on the identification of the cleavage products of this reaction, and provides a method for cleaving a neisserial polypeptide, comprising the step of mixing the polypeptide with a lactoferrin enzyme. The invention also provides polypeptides obtainable by this process (i.e. the cleavage products of the lactoferrin digestion) which might be useful in the preparation of anti-meningococcal vaccines. Proteins of particular interest are meningococcal proteins 287 and App.
Owner:NOVARTIS AG

Mixing lyophilised meningococcal vaccines with non-hib vaccines

An aqueous immunogen formulation is used to reconstitute a lyophilised component including conjugates of capsular saccharides from Neisseria meningitidis serogroups A, C, W135 and Y, thereby producing a combined vaccine. The aqueous formulation can include various immunogens but does not include a Hib conjugate.
Owner:GLAXOSMITHKLINE BIOLOGICALS SA

Novel synthetic oligomers of neisseria meningitis serogroup x and process of preparing them

InactiveUS20170066794A1Short time durationMinimizeEsterified saccharide compoundsAntibacterial agentsBacterial meningitisChemical synthesis
The present invention relates to synthesis of novel higher oligomers and process of preparing the same. In particular the present invention relates to the chemical synthesis of oligomers of Neisseria meningitidis serogroup X (‘hereinafter Men-X), more particularly tetramer. The present invention provides Men-X capsular oligomers obtained from synthetic pathway using purified saccharides of specific chain length and provides said novel oligomers as candidates for the development of conjugate vaccine against bacterial meningitis caused due to Men-X infections.
Owner:MSD WELLCOME TRUST HILLEMAN LAB PVT LTD

Visualization method for rapidly detecting neisseria gonorrhoeae by utilizing recombinase polymerase isothermal amplification technology

The invention belongs to the technical field of molecular biological detection, relates to a detection method for pathogenic microorganisms, and in particular relates to a visualization method for rapidly detecting neisseria gonorrhoeae by utilizing a recombinase polymerase isothermal amplification technology. According to the method, by combining the recombinase polymerase isothermal amplification technology and fluorescent dye developing, rapid amplification of neisseria gonorrhoeae nucleic acids can be realized under the condition that a PCR (Polymerase Chain Reaction) instrument and any other heat cycle equipment are not used. The results are identified by observing the color change of the reaction system with naked eyes. According to related reagents provided by the invention, the neisseria gonorrhoeae in samples can be rapidly detected by virtue of simple treatment of to-be-detected samples, and the detection method has the advantages of being simple in operation, high in specificity, capable of determining the results with naked eyes, and the like, and is applicable to clinical diagnosis and individual early screening.
Owner:INST OF PATHOGEN BIOLOGY CHINESE ACADEMY OF MEDICAL SCI

Combined Meningococcal Conjugates With Common Carrier Protein

Carrier-induced epitopic suppression is of particular concern where multiple conjugates with the same carrier protein are administered simultaneously. To avoid the suppression, the invention minimises the amount of unconjugated carrier protein in a vaccine. The invention provides a composition for immunising a patient against a disease caused by Neisseria meningitidis, wherein (1) the composition comprises conjugates for at least two of the four meningococcal serogroups A, C, W135 and Y, where at least two of the conjugates have a common carrier protein; and (2) the composition includes the common carrier in an unconjugated form at less than 10 μg / ml.
Owner:GLAXOSMITHKLINE BIOLOGICALS SA

Polynucleotides for the amplification and detection of neisseria gonorrhoeae

Disclosed herein are primers and probes related to the detection of Neisseria gonorrhoeae via nucleic acid amplification testing (NAAT), for example to amplify and determine the presence of N. gonorrhoeae nucleic acids present in test samples. Specifically the present disclosure describes primers and probes that bind to the small subunit rRNA (cytosine (967)-C(5))-methyltransferase or rsmB gene of N. gonorrhoeae for detection via loop mediated isothermal amplification (LAMP) and molecular beacon hybridization.
Owner:TALIS BIOMEDICAL CORP

Two-component system that controls bacterial membrane synthesis

The present invention discloses a mutant Neisseria having extensive membrane blebbing, both an indicium and a cause of virulence in the gonococcus and meningococcus. Methods are disclosed for making and characterizing the mutant, bmrRS. Methods are disclosed for isolating bmrRS membranes for use as a vaccine. Methods are also disclosed for the use of the mutant for determining the virulence of clinical samples of N. gonorrhoeae and N. meningitidis. Methods are also disclosed for the screening of antibiotics targeted to virulent Neisseria.
Owner:UNIV OF IOWA RES FOUND

Reagents and methods for detecting neisseria gonorrhoeae

This invention provides compositions and methods for detecting Neisseria gonorrhoeae in a sample. This invention also provides related reaction mixtures, kits, systems, and computers.
Owner:ROCHE MOLECULAR SYST INC

85kDa neisserial antigen

An 85kDa antigen from Neisseria meningitidis and Neisseria gonorrhoeae has been cloned, sequenced and expressed. The antigen is common to diverse strains, serogroups and serotypes of N. meningitidis, and also to N. gonorrhoeae, N. polysaccharia and N. lactamica. The protein sequences of N. meningitidis (serogroups A and B) and N. gonorrhoeae are highly homologous.
Owner:STATENS INST FOR FOLKEHELSE +1
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products